BioPharmSignal logoBioPharmSignal

Biotech News

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

SOLIGENIX (SNGX)SOLIGENIXClinical readout

SNGX (SNGX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is sngx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

REGNRegeneron Pharmaceuticals2026-10-01 15:30 EST

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

CNTBConnect Biopharma Holdings Limited2026-09-30 11:00 EST

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

CNTBConnect Biopharma Holdings Limited2026-09-15 11:00 EST

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

HCMHUTCHMED2026-08-31 00:00 EST

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

REGNRegeneron Pharmaceuticals2026-10-06 11:00 EST

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

ELDNEledon Pharmaceuticals, Inc.2026-09-03 11:00 EST

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026

MLTXMoonLake Immunotherapeutics2026-08-10 11:00 EST

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

STTKShattuck Labs2026-10-01 11:00 EST

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

View all latest news

SOLIGENIX

Rare-Disease Biopharmaceutical Company Soligenix develops therapies for rare diseases with substantial unmet need. Its pipeline has included oncology, inflammatory-disease and biodefense programs. HyBryte HyBryte is a synthetic hypericin photodynamic therapy developed for cutaneous T-cell lymphoma. Its confirmatory Phase 3 FLASH2 study...

Recent company news

SNGXSOLIGENIX2026-08-07 11:30 EST

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

SNGXSOLIGENIX2026-06-08 11:30 EST

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

SNGXSOLIGENIX2026-05-26 11:30 EST

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

SNGXSOLIGENIX2026-05-08 11:30 EST

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

SNGXSOLIGENIX2026-04-28 11:30 EST

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Stock data

Close
0.36 USD
Market cap
11.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States